Rachel Klemovitch, Assistant Editor11.21.23
Roswell Park Comprehensive Cancer Center launched PanHeme, a test using next-generation gene sequencing to diagnose blood cancers and mutations in under 72 hours.
A test was recently licensed to Agilent Technologies for commercial development. According to the company, PanHeme screens DNA and RNA looking for deletions, insertions, fusions and other variations and mutations in the chromosomes to help diagnose patients.
With a faster turnaround, according to Roswell Park, PanHeme helps reduce possible time in therapy as a result of late detected cancers.
Hematologist James Thompson in the Roswell Park department of medicine commented, “the information provided by the PanHeme test allows us to offer clinical trials specifically designed for those with the mutation and avoid committing three weeks to a run of therapy that might not be effective.”
Roswell Park states PanHeme can identify possible gene mutations related to myelodysplastic syndromes (MDS), leukemia, multiple myeloma, lymphoma, and myeloproliferative neoplasms (MPNs).
Thompson added, “it definitely changes the type of therapy we prescribe, and it’s clinical important to have that result in a timely manner.”
A test was recently licensed to Agilent Technologies for commercial development. According to the company, PanHeme screens DNA and RNA looking for deletions, insertions, fusions and other variations and mutations in the chromosomes to help diagnose patients.
With a faster turnaround, according to Roswell Park, PanHeme helps reduce possible time in therapy as a result of late detected cancers.
Hematologist James Thompson in the Roswell Park department of medicine commented, “the information provided by the PanHeme test allows us to offer clinical trials specifically designed for those with the mutation and avoid committing three weeks to a run of therapy that might not be effective.”
Roswell Park states PanHeme can identify possible gene mutations related to myelodysplastic syndromes (MDS), leukemia, multiple myeloma, lymphoma, and myeloproliferative neoplasms (MPNs).
Thompson added, “it definitely changes the type of therapy we prescribe, and it’s clinical important to have that result in a timely manner.”